Дибикор®

General characteristics. Structure:

Taurine of 250 mg and excipients: cellulose of microcrystallic 23 mg, starch of potato 18 mg, gelatin of 6 mg, silicon dioxide colloid (Aerosil) of 0,3 mg, calcium stearate of 2,7 mg.
Description. Tablets of white or almost white color, ploskotsilindrichesky with risky and a facet.

Pharmacological properties:

Pharmacodynamics. Taurine is a natural product of exchange of sulfur-containing amino acids: cysteine, Cysteaminum, methionine. Taurine possesses osmoregulatory and membranoprotektorny properties, positively influences phospholipidic structure of membranes of cells, normalizes exchange of calcium ions and potassium in cells. At taurine properties of a brake neurotransmitter are revealed, it possesses
antistressorny action, can regulate release of GAMK, adrenaline, prolactin and other hormones, and also to regulate answers to them. Dibikor improves metabolic processes in heart, a liver and other bodies and fabrics. At chronic diffusion diseases of a liver Dibikor increases a blood stream and reduces expressiveness 2 cytolysis. Treatment by Dibikor at the cardiovascular insufficiency (CI) leads to reduction of developments of stagnation in small and big circles of blood circulation: intracardiac diastolic pressure decreases, contractility of a myocardium (the maximum speed of reduction and relaxation, indexes of contractility and a relaxation) increases. Drug moderately reduces arterial pressure at patients with arterial hypertension and practically does not influence its level at patients with SSN. Dibikor reduces the by-effects arising at overdose of cardiac glycosides and blockers of "slow" calcium channels, increases working capacity at heavy exercise stresses. At a diabetes mellitus approximately in 2 weeks after the beginning of reception of Dibikor sugar level in blood decreases. Also considerable reduction of concentration of triglycerides, to a lesser extent - cholesterol level, reduction of an aterogennost of lipids of plasma is noticed. At prolonged use of drug (about 6 months) improvement of a microcirculator blood-groove of an eye is noted.

Pharmacokinetics. After a single dose of 500 mg of Dibikor active ingredient taurine in 15-20 minutes is defined in blood, reaching a maximum in 1,5-2 hours. Completely drug is removed in a day.

Indications to use:

• cardiovascular insufficiency of various etiology;
• intoxication caused by cardiac glycosides;
• diabetes mellitus of 1 type;
• a diabetes mellitus 2 types, including with a moderate hypercholesterolemia.

Route of administration and doses:

At heart failure Dibikor accept inside on 250-500 mg (1-2 tablets) 2 times a day in 20 minutes prior to food, a course of treatment – 30 days. The dose can be increased to 2-3 g (8-12 tablets) a day or is reduced to 125 mg (1/2 tablets) by reception. At intoxication cardiac glycosides – not less than 750 mg (3 tablets) a day. 3 At a diabetes mellitus of 1 type – on 500 mg (2 tablets) 2 times a day in combination with an insulin therapy within 3-6 months. At a diabetes mellitus 2 types – on 500 mg (2 tablets) 2 times a day in monotherapy or in combination with other hypoglycemic means for intake. At a diabetes mellitus 2 types, including with a moderate hypercholesterolemia – on 500 mg (2 tablets) 2 times a day, course duration – according to the recommendation of the doctor.

Features of use:

Against the background of Dibikor's reception it is necessary to reduce a dose of cardiac glycosides sometimes twice, depending on sensitivity of patients to cardiac glycosides. The same rule belongs to blockers of "slow" calcium channels.

Side effects:

Allergic reactions to drug components are possible.

Interaction with other medicines:

Dibikor can be applied with other medicines; strengthens an inotropic effect of cardiac glycosides.

Contraindications:

Hypersensitivity to drug. Age up to 18 years (efficiency and safety are not established).

Overdose:

There are no data.

Storage conditions:

Issue conditions:

Without recipe

Packaging:

Tablets of 250 mg. On 30 or 60 tablets in banks of orange glass. On 10 tablets in a blister strip packaging. To bank or 3 or 6 blister strip packagings together with the application instruction place in a cardboard pack.